It has been reported that genomic alterations of KRAS, TP53, BRAF, and MET are associated with increased expression of PD-L1in NSCLC patients [10, 11], while EGFR and STK11 mutations are correlated with negative/low PD-L1 expression [11, 12], whereas genomic features related to PD-L1 are different among various study populations, antibody clones, and experimental platforms. The gene discussed is TP53; the disease is non-small cell lung carcinoma.